The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines.
about
Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-RafThe farnesyl transferase inhibitor RPR-130401 does not alter radiation susceptibility in human tumor cells with a K-Ras mutation in spite of large changes in ploidy and lamin B distributionPhase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancerInhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells.Farnesyltransferase inhibitors: mechanism and applications.Lipid posttranslational modifications. Farnesyl transferase inhibitors.A farnesylated G-protein suppresses Akt phosphorylation in INS 832/13 cells and normal rat islets: regulation by pertussis toxin and PGE₂.Farnesyltransferase inhibitors in breast cancer therapy.Transformation by Hras(G12V) is consistently associated with mutant allele copy gains and is reversed by farnesyl transferase inhibition.Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies.A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemiaClinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action.Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies.Lonafarnib in cancer therapy.Hematopoietic cell fate and the initiation of leukemic properties in primitive primary human cells are influenced by Ras activity and farnesyltransferase inhibitionClinical activity of tipifarnib in hematologic malignancies.Inhibition of farnesyltransferase: a rational approach to treat cancer?Ras as a therapeutic target in hematologic malignancies.Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies.Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma.Lonafarnib for cancer and progeria.Therapeutic strategies for targeting ras proteins.The kinetochore protein Cenp-F is a potential novel target for zoledronic acid in breast cancer cells.The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity.Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro.Farnesyltransferase inhibitor SCH-66336 downregulates secretion of matrix proteinases and inhibits carcinoma cell migration.Resistance to farnesyltransferase inhibitors in Bcr/Abl-positive lymphoblastic leukemia by increased expression of a novel ABC transporter homolog ATP11a.The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells.Synergistic cytotoxic effects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors.Farnesyl transferase inhibitors.Synergistic effect of farnesyl transferase inhibitor lonafarnib combined with chemotherapeutic agents against the growth of hepatocellular carcinoma cells.Concepts and advances in cancer therapeutic vulnerabilities in RAS membrane targeting.
P2860
Q24598824-4E0AB02D-E2D3-4E31-A6A5-ECD0419234F2Q24805139-05031629-A34A-43A1-AF5E-60F478DF5053Q28240692-8F07A7D3-47A7-417F-BD6B-1FA4DC150689Q31115129-1993EAB1-ACE7-4F5B-83B3-2333F52EE343Q34481874-492906AE-A462-4871-B28E-0BEC16B740D9Q34651253-B24309F5-70B0-4AEF-B125-F6C3B95AC967Q34884341-E664CC6F-DFA0-4DC8-A15F-4DA608C949C2Q35004480-8276A851-00D9-4A8C-9A94-2829E67FAB5BQ35044902-9F9EECF4-15A4-4625-AC18-8DED50C9E5BEQ35091519-DDF33236-905E-4AC0-B5A3-9F63CCDE047DQ35628954-8EF0FAF2-1305-4136-85A4-ED3F14A0B2E7Q35932017-71218A8D-4382-434A-817F-1833E2A90AE5Q36429603-D5908A7D-7735-43DB-96F3-CFC24278E67FQ36491847-CF379191-1871-4E3A-9874-C81FC52C3F84Q36701461-69EBE164-5B9D-40F6-9E9A-8CDF613136C7Q36736368-003D9211-4553-4E76-8C8F-6F441C237D53Q36828655-CA6F4ECD-1868-48F9-A651-88A23647159AQ36866611-90EF40B7-D8EB-43BB-B644-5B2FDDDA3747Q36946766-F9B20C4E-C9BB-4E2E-855D-7B2D1D834957Q37723277-E0CDD2FF-6B12-4D2C-A802-C60EF0E92A93Q38012480-2B1EC0E3-42BF-490A-A45F-EF85F83AF795Q39262217-8734604E-1A44-4B20-98B2-80108855106FQ39762559-C61BEF9E-5A0B-42D6-A600-81BDA8F3841CQ40399733-F0524D07-1D8B-46B3-B1E7-1EAB5079A37CQ40423639-DD0C7C43-DB6F-4083-B439-4E067EB316C0Q40478997-245FFF4C-2C9A-4366-9ABB-BE8ADCE559D4Q42742534-FC4F62E3-0DF9-417A-A02B-BE01FC554314Q44319734-18C61C0F-92C7-4951-91F1-688E64A37DB7Q44529443-1025DA1F-95A6-4139-8E3B-A74B2ABC4EE7Q46456381-E8E3734C-4744-4F47-902C-E6FA674831E6Q47094177-FF494EE7-7298-413C-894E-C88D1E124018Q47333014-DB7A5962-D1D7-45B4-9F6D-CE72963B8479
P2860
The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
The farnesyl transferase inhib ...... sitive human tumor cell lines.
@ast
The farnesyl transferase inhib ...... sitive human tumor cell lines.
@en
type
label
The farnesyl transferase inhib ...... sitive human tumor cell lines.
@ast
The farnesyl transferase inhib ...... sitive human tumor cell lines.
@en
prefLabel
The farnesyl transferase inhib ...... sitive human tumor cell lines.
@ast
The farnesyl transferase inhib ...... sitive human tumor cell lines.
@en
P2093
P356
P1476
The farnesyl transferase inhib ...... sitive human tumor cell lines.
@en
P2093
A G Taveras
L Armstrong
P Kirschmeier
P356
10.1006/EXCR.2000.5076
P407
P577
2001-01-01T00:00:00Z